NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer

Post time 2026-10-20 17:56:24

journal：Journal of Clinical Oncology

Authors：Steven J. Chmura; Kathryn A. Winter; Wendy A. Woodward; Virginia F. Borges; Joseph K. Salama; Hania A. Al-Hallaq; Martha M. Matuszak; Michael T. Milano; Nora T. Jaskowiak; Reshma Jagsi; Peter Kuhn; Anthony Lucci; Salyna Meas; Stephanie N. Shishido; Jeremy Mason; Jose G. Bazan; Robert A. Nordal; David Y. Lee; Benjamin D. Smith; Zsolt Gabos; Jason C. Ye; Shannon T. Kahn; Laura A. Vallow; Imran Zoberi; Wajeeha Razaq; Mark V. Mishra; Kristin M. Lupinacci; Jennifer Moughan; Eleftherios P. Mamounas; Julia R. White

Published date：--

DOI：10.1200/jco-26-00201

PDF link：https://ascopubs.org/doi/pdfdirect/10.1200/JCO-26-00201

Article link：https://doi.org/10.1200/jco-26-00201

Article Source：American Society of Clinical Oncology (ASCO)。

Remark：

Post time 2026-10-20 17:56:25

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Other] NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer Copy

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer